Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase-Producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2)

Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase-Producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2)

10.1093/ofid/ofab387

Saved in:
書目詳細資料
Main Authors: Stewart, AG, Paterson, DL, Young, B, Lye, DC, Davis, JS, Schneider, K, Yilmaz, M, Dinleyici, R, Runnegar, N, Henderson, A, Archuleta, S, Kalimuddin, S, Forde, BM, Chatfield, MD, Bauer, MJ, Lipman, J, Harris-Brown, T, Harris, PNA
其他作者: MEDICINE
格式: Article
出版: Oxford University Press (OUP) 2021
主題:
Enterobacterales
ampC β-lactamase
carbapenem
clinical trial
piperacillin-tazobactam
在線閱讀:https://scholarbank.nus.edu.sg/handle/10635/206194
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

因特網

https://scholarbank.nus.edu.sg/handle/10635/206194

相似書籍